In the manuscript "Metabolic syndrome, C-reactive protein and cardiovascular risk in psoriasis patients: a cross-sectional study", with DOI number: 10.1590/abd1806-4841.20186397, published in the Anais Brasileiros de Dermatologia (Brazilian Annals of Dermatology), 2018;93(2):222-8, in the page224.

Where it reads:

###### 

Metabolic syndrome, cardiovascular risk and PASI-defined disease severity parameters according to genders of psoriasis patients

                                                                               Overall     Male        Female      P-value
  ---------------------------------------------------------------------------- ----------- ----------- ----------- ---------
  Number, n (%)                                                                90 (100)    45 (50)     45 (50)      
  Age (years)                                                                  49.0        48.8        49.2         
  PASI                                                                         12.0        13.6        10.4         
  Moderate - Severe PsO (PASI ≥ 10), n (%)                                     50 (55.6)   27 (60.0)   23 (51.1)   0.40
  Mild PsO (PASI \<10)                                                         40 (44.4)   18 (40.0)   22 (48.9)    
  CRP (mean) mg/dL                                                             2.93        2.74        3.11        0.59
  Metabolic syndrome (NCEPT- ATP III), n (%)                                   39 (43.3)   16 (35.6)   23 (51.1)   0.14
  Obesity (waist circumference \> 102 cm for men, \> 88 cm for women), n (%)   29 (32.2)   10 (22.2)   19 (42.2)   0.04
  Triglycerides (≥150 mg/dL), n (%)                                            35 (38.9)   15 (33.3)   20 (44.4)   0.28
  HDL- cholesterol (\<40 mg/dL in men, \<50 mg/dL in women), n (%)             43 (47.8)   26 (57.8)   17 (37.8)   0.27
  Systemic arterial hypertension (≥130/ ≥85 mmHg), n (%)                       45 (50)     17 (35.6)   29 (64.4)   0.006
  Fasting glucose (≥110 mg/dL), n (%)                                          28 (31.1)   14 (31.1)   14 (31.1)   1.00
  Cardiovascular risk (absolute %)                                             8.7         11.5        5.9         0.002
  ≥ 20%, n (%)                                                                 3 (3.3)     3 (6.6)     0            
  10% ≥ CVR \< 20%, n (%)                                                      29 (32.2)   19 (42.2)   10 (22.2)    
  \< 10%, n (%)                                                                58 (64.4)   23 (51.1)   35 (77.8)    
  Cardiovascular risk *(global assessment)*                                                                         
  High-Intermediate, n (%)                                                     46 (51.1)   22 (48.9)   24 (53.3)   0.83
  Low, n (%)                                                                   44 (43.3)   23 (51.1)   21 (35.6)    

PsO, Psoriasis; PASI, Psoriasis Area and Severity Index; CRP, C-reactive protein; NCEP-ATP III, National Cholesterol Education Program - Adult Treatment Panel III; HDL, high-density lipoprotein.

It should read

###### 

Metabolic syndrome, cardiovascular risk and PASI-defined disease severity parameters according to genders of psoriasis patients

                                                                               Overall     Male        Female      P-value
  ---------------------------------------------------------------------------- ----------- ----------- ----------- ---------
  Number, n (%)                                                                90 (100)    45 (50)     45 (50)      
  Age (years)                                                                  49.0        48.8        49.2         
  PASI                                                                         12.0        13.6        10.4         
  Moderate - SeverePsO (PASI ≥ 10), n (%)                                      50 (55.6)   27 (60.0)   23 (51.1)   0.40
  Mild PsO (PASI \<10)                                                         40 (44.4)   18 (40.0)   22 (48.9)    
  CRP (mean) mg/dL                                                             2.93        2.74        3.11        0.59
  Metabolic syndrome (NCEPT-ATPIII), n (%)                                     39 (43.3)   16 (35.6)   23 (51.1)   0.14
  Obesity (waist circumference \> 102 cm for men, \> 88 cm for women), n (%)   29 (32.2)   10 (22.2)   19 (42.2)   0.04
  Triglycerides (≥150mg/ dL), n (%)                                            35 (38.9)   15 (33.3)   20 (44.4)   0.28
  HDL-cholesterol (\<40mg/ dL in men, \<50 mg/ dL in women), n (%)             43 (47.8)   26 (57.8)   17 (37.8)   0.27
  Systemic arterial hypertension (≥130/ ≥85 mmHg), n (%)                       45 (50)     17 (35.6)   29 (64.4)   0.006
  Fasting glucose (≥110mg/ dL), n (%)                                          28 (31.1)   14 (31.1)   14 (31.1)   1.00
  Cardiovascular risk (absolute %)                                             8.7         11.5        5.9         0.002
  ≥ 20%, n (%)                                                                 3 (3.3)     3 (6.6)     0            
  10% ≤ CVR \< 20%, n (%)                                                      29 (32.2)   19 (42.2)   10 (22.2)    
  \<10%, n (%)                                                                 58 (64.4)   23 (51.1)   35 (77.8)    
  Cardiovascular risk *(global assessment)*                                                                         
  High-Intermediate, n (%)                                                     46 (51.1)   22 (48.9)   24 (53.3)   0.83
  Low, n (%)                                                                   44 (43.3)   23 (51.1)   21 (35.6)    

PsO, Psoriasis; PASI, Psoriasis Area and Severity Index; CRP, C-reactive protein; NCEP ATP III, National Cholesterol Education Program - Adult Treatment Panel III; HDL, high density lipoprotein.
